Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure

Arturi, Franco; Succurro, Elena; Miceli, Sofia; Cloro, C; Ruffo, Mariafrancesca; Maio, Raffaele; Perticone, Maria; Sesti, Giorgio; Perticone, Francesco

doi:10.1007/s12020-016-1166-4

Cited by 57 publications

(54 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The newest class of medications, which treat both type 2 diabetes and obesity, is the GLP-1 analogues. Increasing evidence suggests that these medications are efficacious not only at reducing weight, but also at improving the comorbidities of obesity, including cardiovascular disease, non-alcoholic steatohepatitis [35,36] and overall mortality [37–39]. Similar results to the most recent study, above, with liraglutide were demonstrated by this study group in the shorter-term.…”

supporting

confidence: 85%

Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook

Farr

Mantzoros

2017

Metabolism

View full text Add to dashboard Cite

supporting

confidence: 85%

Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook

Farr

Mantzoros

2017

Metabolism

View full text Add to dashboard Cite

“…Previous smallsample, retrospective studies showed that GLP-1 was associated with favourable effects that GLP-1 significantly improved LV function, functional status, and the QoL [138]; and that GLP-1 reduced the risk of HHF, all-cause hospitalization, and death in T2DM [139]. Another study involving 32 T2DM patients with a history of CHF provided evidence that treatment with liraglutide is associated with improvements in cardiac function and functional capacity [140]. However, in LEADER, the rate of the primary composite outcome in the time-to-event analysis (the first occurrence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke) among patients with T2DM and high cardiovascular risk was lower with liraglutide than with placebo, whereas the number of HHF was reduced non-significantly in the active arm [141].…”

Section: Glucagon-like Peptide-1 (Glp-1)mentioning

confidence: 95%

Reappraisal on pharmacological and mechanical treatments of heart failure

Liang

Zhao

Zhang

et al. 2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

Heart failure (HF) is a highly frequent disorder with considerable morbidity, hospitalization, and mortality; thus, it invariably places pressure on clinical and public health systems in the modern world. There have been notable advances in the definition, diagnosis, and treatment of HF, and newly developed agents and devices have been widely adopted in clinical practice. Here, this review first summarizes the current emerging therapeutic agents, including pharmacotherapy, device-based therapy, and the treatment of some common comorbidities, to improve the prognosis of HF patients. Then, we discuss and point out the commonalities and areas for improvement in current clinical studies of HF. Finally, we highlight the gaps in HF research. We are looking forward to a bright future with reduced morbidity and mortality from HF.

show abstract

“…Sitagliptin and liraglutide have been shown to improve diastolic function in the short term [11][12][13][14] and diabetes mortality increases with E/e′. 15 This may be the first report of differential effects of GLP-1 analogue and DPP-4 inhibitors on cardiac diastolic function with follow-up as long as 48 months.…”

Section: Discussionmentioning

confidence: 81%

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors

Hiramatsu

Asano

Mabuchi

et al. 2018

Eur J Clin Investigation

View full text Add to dashboard Cite

IntroductionDiabetes mellitus is a progressive disease with cardiovascular complications. This study evaluated the effects of liraglutide, a glucagon‐like peptide‐1 analogue and the dipeptidyl peptidase 4 inhibitors sitagliptin and linagliptin on cardiac function in type 2 diabetes patients with renal impairment.Materials and MethodsA total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated. Blood glucose, glycosylated haemoglobin and serum creatinine were assayed every 3 months for 48 months. Echocardiography was performed every 12 months for 48 months.ResultsCompared with baseline, fasting glucose, postprandial glucose, and systolic and diastolic pressure, but not estimated glomerular filtration rate, significantly decreased in all three groups. Albuminuria decreased from 24 to 48 months with liraglutide, but only from 24 to 30 months with sitagliptin and linagliptin. Diastolic function, assessed by E/e′ or left atrial dimension improved only with liraglutide.ConclusionsLiraglutide was effective for glucose and blood pressure control, reduced albuminuria and improved diastolic function. Diastolic function was not improved by sitagliptin and linagliptin.

show abstract

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure

Abstract: These data provide evidence that treatment with liraglutide is associated with improvement of cardiac function and functional capacity in failing post-ischemic type-2 diabetes mellitus patients.

Cited by 57 publications

References 47 publications

Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook

Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook

Reappraisal on pharmacological and mechanical treatments of heart failure

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors

Contact Info

Product

Resources

About